These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8373757)

  • 21. [Use of iumeks in the combined therapy of parkinsonism patients ].
    Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA
    Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
    [No Abstract]   [Full Text] [Related]  

  • 22. Selegiline, pregnancy, and Parkinson's disease.
    Kupsch A; Oertel WH
    Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
    Hamaue N; Minami M; Terado M; Hirafuji M; Endo T; Machida M; Hiroshige T; Ogata A; Tashiro K; Saito H; Parvez SH
    Neurotoxicology; 2004 Jan; 25(1-2):205-13. PubMed ID: 14697895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 25. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
    Schneider E
    J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 28. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 29. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
    Youdim MB; Riederer PF
    Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
    [No Abstract]   [Full Text] [Related]  

  • 31. Mid-stage parkinsonism with mild motor fluctuations.
    Tolosa E; Valldeoriola F
    Clin Neuropharmacol; 1994; 17 Suppl 2():S19-31. PubMed ID: 9358192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoamine oxidase inhibitors and their pharmacological significance.
    Sandler M
    Acta Neurol Scand Suppl; 1983; 95():37-41. PubMed ID: 6428147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Monoamine oxidase inhibitors].
    Naoi M; Nagatsu T
    Nihon Rinsho; 1991 Sep; 49(9):2040-5. PubMed ID: 1960872
    [No Abstract]   [Full Text] [Related]  

  • 34. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Big first scored with nerve diseases.
    Lewin R
    Science; 1989 Aug; 245(4917):467-8. PubMed ID: 2502841
    [No Abstract]   [Full Text] [Related]  

  • 36. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 37. Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.
    Reiderer P; Reynolds GP
    Br J Clin Pharmacol; 1980 Jan; 9(1):98-9. PubMed ID: 6766730
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
    Chen JJ; Swope DM
    J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroprotection for Parkinson's disease: prospects and promises.
    Olanow CW; Schapira AH; Agid Y
    Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R; Lecht S; Lazarovici P
    Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.